EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Anticoagulation Among Patients Hospitalized for COVID-19

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Claire L Vale, Peter J Godolphin, David J Fisher, Julian P T Higgins, Alexandra McAleenan, Francesca Spiga, Tobias Tritschler, Pedro Gabriel Melo de Barros E Silva, David D Berg, Jeffrey S Berger, Lindsay R Berry und 48 weitere

Annals of Internal Medicine · 2025

DOI: 10.7326/annals-24-00800 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group und 59 weiteren Autor:innen. Hauptthemen laut MEDLINE: Anticoagulants, COVID-19 Drug Treatment. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent. PURPOSE: To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes. DATA SOURCES: Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov with no restriction by trial status or language. STUDY SELECTION: Eligible randomized trials assigned patients hospitalized for COVID-19 to higher- versus lower-dose anticoagulation. DATA EXTRACTION: 20 eligible trials provided data in a prospectively agreed format. Two further studies were included based on published data. The primary outcome was all-cause mortality 28 days after randomization. Secondary outcomes were progression to invasive mechanical ventilation or death, thromboembolic events, and major bleeding. DATA SYNTHESIS: Therapeutic- compared with prophylactic-dose anticoagulation with heparins reduced 28-day mortality (OR, 0.77 [95% CI, 0.64 to 0.93]; I 2 = 29%; 11 trials, 6297 patients, of whom 5456 required low or no oxygen at randomization). The ORs for 28-day mortality were 1.21 (CI, 0.93 to 1.58; I 2 = 0%) for therapeutic-dose compared with intermediate-dose anticoagulation (6 trials, 1803 patients, 843 receiving noninvasive ventilation at randomization) and 0.95 (CI, 0.76 to 1.19; I 2 = 0%; 10 trials, 3897 patients, 2935 receiving no or low oxygen at randomization) for intermediate- versus prophylactic-dose anticoagulation. Treatment effects appeared broadly consistent across predefined patient subgroups, although some analyses were limited in power. Higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events, but a greater risk for major bleeding. CONCLUSION: Therapeutic-dose compared with prophylactic-dose anticoagulation reduced 28-day mortality. Mortality was similar for intermediate-dose compared with prophylactic-dose anticoagulation and higher for therapeutic-dose compared with intermediate-dose anticoagulation, although this comparison was not estimated precisely. PRIMARY FUNDING SOURCE: No direct funding. (PROSPERO: CRD42020213461).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsCOVID-19 Drug TreatmentHumansCOVID-19HospitalizationHemorrhageThromboembolismRandomized Controlled Trials as TopicHeparinSARS-CoV-2Respiration, Artificial

Substanzen

AnticoagulantsHeparin

Zitieren

APA

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Vale, C. L., Godolphin, P. J., Fisher, D. J., Higgins, J. P. T., McAleenan, A., Spiga, F., Tritschler, T., de Barros E Silva, P. G. M., Berg, D. D., Berger, J. S., Berry, L. R., Bikdeli, B., Blondon, M., Bohula, E. A., Cattaneo, M., Colombo, R., Coluccio, V., DeSancho, M. T., …, & Diaz, J. V. (2025). Anticoagulation Among Patients Hospitalized for COVID-19. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-00800

Vancouver

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Vale CL, Godolphin PJ, Fisher DJ, Higgins JPT, McAleenan A, et al. Anticoagulation Among Patients Hospitalized for COVID-19. Annals of Internal Medicine. 2025. doi:10.7326/annals-24-00800

BibTeX
@article{WHORapidEvidenceAppraisalforCOVIDTherapiesREACTWorkingGroup2025,
  author = {WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group and Vale, Claire L and Godolphin, Peter J and Fisher, David J and Higgins, Julian P T and McAleenan, Alexandra and Spiga, Francesca and Tritschler, Tobias and de Barros E Silva, Pedro Gabriel Melo and Berg, David D and Berger, Jeffrey S and Berry, Lindsay R and Bikdeli, Behnood and Blondon, Marc and Bohula, Erin A and Cattaneo, Marco and Colombo, Riccardo and Coluccio, Valeria and DeSancho, Maria T and Farkouh, Michael E and Fuster, Valentin and Girardis, Massimo and Hochman, Judith S and Jensen, Thomas P and Jha, Vivekanand and Jüni, Peter and Kirtane, Ajay J and Lawler, Patrick and Le Gal, Grégoire and Lecumberri, Ramon and Lentz, Steven R and Lopes, Renato D and Lorenzi, Elizabeth and Marietta, Marco and Miranda, Carlos Henrique and Morici, Nuccia and Morpeth, Susan C and Morrow, David A and McQuilten, Zoe K and Muñoz-Rivas, Nuria and Neal, Matthew D and Pant, Suman and Parikh, Sahil A and Perepu, Usha and Sadeghipour, Parham and Sethi, Sanjum and Sholzberg, Michelle and Spyropoulos, Alex C and Stone, Gregg W and Talasaz, Azita Hajhossein and Tong, Steven and Totterdell, James and Venkatesh, Balasubramanian and Wu, Maddalena Alessandra and Zarychanski, Ryan and Zuily, Stephane and Viry, Julie and Rylance, Jamie and Adhikari, Neill K J and Diaz, Janet V},
  title = {Anticoagulation Among Patients Hospitalized for COVID-19},
  journal = {Annals of Internal Medicine},
  year = {2025},
  doi = {10.7326/annals-24-00800}
}
Kostenlos starten →